Guo X, Ma W, Wu H, et al. - Researchers performed a retrospective review to determine the incidence, clinical features, as well as prognosis of lung cancer patients with synchronous bone metastasis (SBM) and to explore the prognostic factors of this patient population. They followed 938 patients (34.3%) with SBM and a median survival of 11.53 months was noted, and the 1-, 2-, and 5-year overall survival rate was estimated to be 51, 17, and 8%, respectively. In multivariable Cox regression, poor prognosis in relation to history of smoking as well as high level of neuron specific enolase was revealed, while adenocarcinoma histological type was related to better survival. Overall, a relatively high prevalence of SBM, which was associated with poor survival, was evident in lung cancer patients. Diverse prognosis was exhibited by lung cancer patients who developed SBM. Among all the pathological varieties, the division of adenocarcinoma indicated different prognosis of the lung cancer cases with SBM. These data highlight the value of pathological diagnosis on prognostic determinants in lung cancer cases with SBM.